Pentadecapeptide

Pentadecapeptide refers to any peptide composed of exactly 15 amino acid residues. In the context of peptide therapy and research, the term is most closely associated with BPC-157 (Body Protection Compound-157), which is itself a pentadecapeptide derived from human gastric juice. However, pentadecapeptides as a class represent an interesting size range in peptide biology — large enough to have complex three-dimensional structures and specific receptor interactions, yet small enough to be synthesized efficiently and maintain reasonable bioavailability.

The gastric pentadecapeptide BPC-157 has been the most extensively studied member of this class for regenerative applications. Its 15-amino acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) was identified as the minimum active fragment from a larger protective protein complex found in gastric juice. Research has shown this specific sequence retains the full protective and regenerative activity of the parent protein.

Beyond BPC-157, other pentadecapeptides have been investigated in various biomedical contexts. The 15-amino acid length provides sufficient structural complexity for bioactive peptides to engage in meaningful molecular interactions while remaining within a size range amenable to chemical synthesis and pharmaceutical formulation. Antimicrobial pentadecapeptides have been studied for infectious disease applications, and various synthetic pentadecapeptides have been designed for targeted therapeutic activities.

The study of pentadecapeptides and other short bioactive peptides has contributed to the broader understanding of how small protein fragments can exert potent biological effects. This research has implications for drug design, as short peptides offer advantages including lower production costs, reduced immunogenicity compared to large proteins, and the potential for chemical modification to improve stability and bioavailability.